RESUMO
Objective To investigate the changes and clinical significance of serum tumor markers in patients with non-small cell lung cancer before and after gefitinib targeted therapy.Methods 80 cases of non-small cell lung cancer patients in our hospital from June 2015 to May 2017 were divided into control group and observation group randomly,40 cases in each group.The control group were treated with docetaxel conventional chemotherapy,and the observation group were treated with gefitinib targeted therapy.The clinical treatment effect,changes of serum tumor markers cancer antigen125 (CA125),carcinoembryonic antigen (CEA),neuron specific enolase (NSE) and adverse reactions were observed and compared between the two groups before and after treatment.Results The effective rate and disease control rate of the observation group were higher than that in the control group,with statistically significant difference (P ＜ 0.05).The levels of serum tumor markers CA125,CEA and NSE in the control group and the observation group before treatment were not significantly different (P ＞ 0.05).After 1 months of treatment,the levels of serum tumor markers CA125,CEA and NSE in the two groups were all decreased,and the level of serum tumor markers,CA125,CEA and NSE in the observation group were lower than those in the control group,with statistically significant difference.The incidence of adverse reactions in the observation group was lower than that in the control group (P ＜ 0.05),with statistically significant difference.Conclusions Gefitinib is effective in the treatment of non-small cell lung cancer.It reduces the level of serum tumor markers CA125,CEA,NSE,and reduces postoperative adverse reactions.It is worthy of clinical application.
RESUMO
Objective To study the effect of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) gefitinib on cancer cell apoptosisand survival time of patients with advanced non-small cell lung cancer (NSCLC).Methods A total of 126 cases of patients diagnosised as NSCLC stage Ⅲ B-ⅣV in our hospital during June 2013-October 2015 were randomly divided into group A received AC chemotherapy,group B received gefitinib,and group C received AC chemotherapy combined with gefitinib therapy.The progression free survival (PFS) rate and objective response rate (ORR) were measured during 12 months follow-up,tumor markers contents in serum and the mRNA expression of apoptosis molecules in tumor lesions were measured.Results The 12-month ORR and PFS of group C were significantly higher than those in groups A and B.The 12-month ORR and PFS of group B were significantly higher than those in group A.For 1 cycle after treatment,serum carcinoembryonic antigen (CEA),cytokeratin 19 (CY-FRA21-1),and thymidine kinase-1 (TK-1) contents among three groups were significantly lower than those before treatment.Caspase-3,Caspase-8,and Caspase-9 mRNA expressions in tumor were significantly higher than those before treatment.For 1 cycle after treatment,serum CEA,CYFRA21-1,and TK-1 contents of group C were significantly lower than groups A and B.Caspase-3,Caspase-8,and Caspase-9 mRNA expressions in tumor were significantly higher than those groups A and B,and serum CEA,CYFRA211,and TK-1 contents of group B were significantly lower than group A.Caspase-3,Caspase-8,and Caspase-9 mRNA expressions in tumor were significantly higher than thsoe of group A.Conclusions Gefitinib combined with intravenous chemotherapy can prolong the survival time of patients with advanced NSCLC and kill tumor cells,induce apoptosis.
RESUMO
Objective To investigate the short-term efficacy and safety of gefitinib combined with dendritic cells-cytokine induced killer (DC-CIK) cells in the treatment of advanced lung adenocarcinoma.Methods Fifty patients with lung adenocarcinoma who in previous had underwent radiotherapy and first-line chemotherapy failure received DC-CIK in combination with gefitinib treatment,blood count changes,imaging data,carcinoembryonic antigen and changes in the quality of life before and after treatment were compared and evaluated.Results DC-CIK could improve effectively and relieve bone marrow suppression response after chemotherapy and significantly increase the WBC content of blood (P ＜ 0.01).After treatment,the tumor carcinoembryonic antigen (CEA) was significantly lower in patients (P ＜ 0.01).Fifty cases of patients in complete remission (CR) were 0 cases,partial remission (PR) were 24 cases,stable disease (SD) were 17 cases and progression (PD) were 9 cases,and the response rates (RR) were 48％;The quality of life of patients was significantly improved (P ＜ 0.05).Common adverse reactions were rash,diarrhea,chill and fever,but mild symptoms could be relieved after symptomatic treatment.Conclusions Gefitinib with autologous DC-CIK cell infusion second-line treatment of advanced lung cancer have a certain short-term efficacy,without significant adverse reactions.Gefitinib with autologous DC-CIK cell therapy can mitigate the response of bone marrow suppression in patients with advanced lung cancer and improve the quality of life of patients.Long-term effect remains to be investigated.